Acorda Therapeutics (ACOR) Misses Q4 EPS by 102c

Acorda Therapeutics (NASDAQ: ACOR) reported Q4 EPS of ($2.50), $1.02 worse than the analyst estimate of ($1.48). Revenue for the quarter came in at $38.16 million versus the consensus estimate of $34 million.

“We have improved our financial position materially through the sale of our manufacturing operations in Chelsea and our restructuring, which also have reduced both our annual operating expenses and cost of goods for INBRIJA,” said Ron Cohen, M.D., Acorda’s President and Chief Executive Officer. “In 2020, we continued to improve access to INBRIJA and saw excellent results from our new patient education and training programs; for example, approximately 1,250 patients who had either never filled or had discontinued their original INBRIJA prescriptions responded to our educational outreach and training by returning to therapy. We also saw quarter over quarter growth in INBRIJA despite the substantial negative impact of COVID-19, and believe we are well-positioned for further growth when the pandemic subsides. We also believe that the reduced cost of goods for INBRIJA will help potentiate commercial partnerships outside the US.”

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c
• Femasys Inc. (FEMY) Misses Q2 EPS by 20c